$HALO Form 8-K

0
521

Form 8-K for HALOZYME THERAPEUTICS INC


11-Jan-2016

Regulation FD Disclosure, Financial Statements and Exhibits

Item 7.01 Regulation FD Disclosure.On January 11, 2016, Halozyme Therapeutics, Inc., a Delaware corporation (“Halozyme”) issued a press release to provide a corporate update on certain strategic programs and to provide financial guidance for 2016. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information is being furnished pursuant to Item 7.01 of this Report and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Halozyme, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to the press release attached hereto as Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

 

Item 9.01. Financial Statements and Exhibits.(d) Exhibits

Exhibit No. Description

99.1 Press release dated January 11, 2016

LEAVE A REPLY

Please enter your comment!
Please enter your name here